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Dear Sir,
I thank you for the opportunity to comment a letter to Acta
Neurochirurgica by Dr. Bongetta and coworkers regarding
low-price tailored hardware for fluorescein imaging during
the resection of malignant gliomas. This group advocates the
use of simple blue light available with commercially available
endoscopy systems for excitation and a commercially avail-
able yellow optical filter fit to the microscope oculars for
observation of fluorescence. The argumentation on their side
is that more affordable systems would help those surgeons
with low budgets and lack of assets to have access to
fluorescence-guided resections.
Similar solutions, on a side note, are also available for ALA
porphyrin imaging, using filters with exactly the same speci-
fications incorporated into currently available Zeiss or Leica
microscopes (D-Light, Storz, Tuttlingen, Germany). In fact,
we ourselves began with handheld filters and a xenon light
source filtered for blue-violet light (375–440 nm) using iden-
tical filters (unpublished data). Unfortunately, even though
these systems are available, their versatility during surgery is
restricted. The full potential of fluorescence imaging comes
from the integration into the operating microscope, which, as
the authors correctly point out, is also the most expensive
solution. So given a confirmed usefulness of a particular
fluorophore for fluorescence-guided resections, cheaper
solutions might be available and the authors are correct in
pointing this out.
However, the authors’ proposal also raises new concerns
regarding fluorescein-guided resections, and that is the pos-
sible influence of the hardware on what the surgeon sees.
Investigators of fluorescein are currently using multitudes
of different doses and timing, between 3 and 20 mg/kg,
administered by either acute injections, injections before
opening of the dura, or injections after induction of anes-
thesia [1–3, 5–9].
Personally, I would prefer (if at all) 3–4 mg fluorescein
administered after induction of anesthesia, according to our
experience with the method [10, 11] using the Zeiss Yellow
560 filter module. This particular mode of use was defined by
Ascerbi et al. [1, 2] using the same Zeiss filter system, which
has (proprietary) transmission characteristics, and was an im-
portant impetus for currently reconsidering the use of fluores-
cein in malignant glioma and vascular surgery, the former use
first described in 1948 [6]. To this end, it remains to be
established whether the low-cost solution by Bongetta et al.
shows the same type of tissue delineation that appears to be
observed using the Yellow 560 filter and whether earlier obser-
vations can simply be extrapolated to their particular fluoresce-
in imaging solution.
A different hardware solution with differing light source
and detection filter specifications provides new confounders
to a technique, which is already beset with multiple variables.
Unfortunately, the basic problems involving fluorescein
(a marker of blood–brain barrier integrity) [12] for
fluorescence-guided resections remain under investigated.
If given too acutely, fluorescein concentrations will be high
in all perfused tissues and vessels. In this situation, if tissue
is perturbed by surgery, there is unspecific extravasation of
fluorescein unrelated to tumor, especially along the resec-
tion margins. If, conversely, fluorescein is given with too
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long of a delay to the actual resection, there are legitimate
concerns about where the fluorescein is going in the brain,
whereas the problems with unspecific extravasation at the
resection margins remains remain. Tumor-related edema in
the brain, which was intensely investigated in the 1970s
and 1980s, will transverse tissue at a speed exceeding
2 mm per hour [4] in patients. With 2 to 3 h between
administration of fluorescein and interrogation of tissue,
this marker will unspecifically have traversed white matter
up to 5 mm, a worrisome thought in the context of an intra-
operative tumor marker.
These confounders have to be kept in mind for fluorophores
that do not have a specific tumor–fluorophore interaction, as is
the case for fluorescein [3]. Thus, while I agree with Bongetta
et al. that less-costly hardware solutions would be helpful for
dissemination of many techniques in neurosurgery, the biolog-
ical or theoretical basis for any technique needs to be well
defined and the solutions should not provide an additional con-
founder in an already-complex environment.
Sincerely,
Walter Stummer
Acknowledgments This letter describes the unapproved (off-label) use
of an investigational agent (fluorescein).
Compliance with ethical standards
Disclosures Walter Stummer has received consultant fees from Medac
and speakers fees from Zeiss.
Conflicts of interest None.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Acerbi F, Broggi M, Eoli M, Anghileri E, Cavallo C, Boffano C,
Cordella R, Cuppini L, Pollo B, Schiariti M, Visintini S, Orsi C, La
Corte E, Broggi G, Ferroli P (2014) Is fluorescein-guided technique
able to help in resection of high-grade gliomas? Neurosurg Focus
36:E5
2. Acerbi F, Broggi M, Eoli M, Anghileri E, Cuppini L, Pollo B,
Schiariti M, Visintini S, Ori C, Franzini A, Broggi G, Ferroli P
(2013) Fluorescein-guided surgery for grade IV gliomas with a
dedicated filter on the surgical microscope: preliminary results in
12 cases. Acta Neurochir (Wien) 155:1277–1286
3. Diaz RJ, Dios RR, Hattab EM, Burrell K, Rakopoulos P, Sabha N,
Hawkins C, Zadeh G, Rutka JT, Cohen-Gadol AA (2015) Study of
the biodistribution of fluorescein in glioma-infiltrated mouse brain
and histopathological correlation of intraoperative findings in high-
grade gliomas resected under fluorescein fluorescence guidance. J
Neurosurg 3:1–10
4. Gröger U, Huber P, Reulen HJ (1994) Formation and resolution of
human peritumoral brain edema. Acta Neurochir Suppl (Wien) 60:
373–374
5. Li Y, Rey-Dios R, Roberts DW, Valdés PA, Cohen-Gadol AA
(2014) Intraoperative fluorescence-guided resection of high-grade
gliomas: a comparison of the present techniques and evolution of
future strategies. World Neurosurg 82:175–185
6. Moore GE, Peyton WT, French LA, Walker WW (1948) The clin-
ical use of fluorescein in neurosurgery; the localization of brain
tumors. J Neurosurg 5:392–398
7. Okuda T, Yoshioka H, Kato A (2012) Fluorescence-guided surgery
for glioblastoma multiforme using high-dose fluorescein sodium
with excitation and barrier filters. J Clin Neurosci 19:1719–1722
8. Rey-Dios R, Cohen-Gadol AA (2013) Technical principles and
neurosurgical applications of fluorescein fluorescence using a
microscope-integrated fluorescence module. Acta Neurochir
(Wien) 155:701–706
9. Schebesch KM, Proescholdt M, Höhne J, Hohenberger C, Hansen E,
Reimenschneider MJ, Ullrich W, Doenitz C, Schlair J, Lange M,
Brawanski A (2013) Sodium fluorescein-guided resection under the
YELLOW560-nm surgicalmicroscope filter inmalignant brain tumor
surgery—a feasibility study. Acta Neurochir (Wien) 155:693–699
10. Schwake M, Stummer W, Suero Molina EJ, Wölfer J (2015)
Simultaneous fluorescein sodium and 5-ALA in fluorescence-
guided glioma surgery. Acta Neurochir (Wien) 157(5):877–879
11. Stummer W (2015) Fluorescein in brain metastasis and glioma sur-
gery. Acta Neurochir (Wien) 157:2199–2200
12. Stummer W, Götz C, Hassan A, Heimann A, Kempski O (1993)
Kinetics of Photofrin II in perifocal brain edema. Neurosurgery 33:
1075–1081
328 Acta Neurochir (2016) 158:327–328
